SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

Enavatuzumab

Cat. No.: HY-P99361

CAS No.: 1062149-33-0

Target: TNF Receptor

Pathway: Apoptosis

Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description

Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody targeting the receptor of TNF-like weak inducer of apoptosis (TWEAK). TWEAK (Fn14; TNFRSF12A), the natural ligand of the TWEAK receptor (TweakR), stimulates multiple cellular responses. Enavatuzumab induces tumor growth inhibition through direct TweakR signaling and antibody dependent cell-mediated cytotoxicity (ADCC). Enavatuzumab can actively recruits and activates myeloid effectors to kill tumor cells. Enavatuzumab inhibits the growth of various human TweakR-positive cancer cell lines and xenografts in vitro and in vivo [1] [2].

In Vitro

Enavatuzumab (0.1-1000 ng/mL; 4 hours) induces effector cell activation and tumor cell killing in vitro[1].
Enavatuzumab (10 μg/mL; for 24 hours) results in significantly increased migration of immune effector cells toward the tumor cells in SN12C and A375 cells[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line:	Renal carcinoma cell line SN12C, the melanoma cell line A375, the colorectal cancer cell lines HCT116 and DLD-1
Concentration:	0.1, 1, 10, 100, 1000 ng/mL
Incubation Time:	4 hours
Result:	Showed potent tumor cell killing on all TweakR-positive tumor cells tested.

In Vivo

Enavatuzumab (10 mg/kg; IP; three times per week; 7 doses) shows diverse antitumor activities on different xenograft tumors[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	6-week old SCID mice with SN12C or HCT116 or DLD-1 or A375 tumors[1]
Dosage:	10 mg/kg
Administration:	IP; three times per week; 6 doses (DLD-1 model), 7 doses (SN12C model), 9 doses (A375 or HCT116 model)

Result:	Some TweakR-expressing cells, such as SN12C and A375, were sensitive in vivo and in vitro. Some TweakR-expressing cell lines, such as HCT116 and DLD-1, were not sensitive to enavatuzumab treatment in vivo, though both cell lines were effectively killed via ADCC in vitro. Up-regulated the activation markers on splenocytes in SN12C tumor-bearing mice.

REFERENCES

[1]. Shiming Ye, et al. Enavatuzumab, a Humanized Anti-TWEAK Receptor Monoclonal Antibody, Exerts Antitumor Activity through Attracting and Activating Innate Immune Effector Cells. J Immunol Res. 2017;2017:5737159.

[2]. Ludmilla de Plater, et al. Predictive gene signature of response to the anti-TweakR mAb PDL192 in patient-derived breast cancer xenografts. PLoS One. 2014 Nov 6;9(11):e104227.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA